Toni K. Choueiri, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses how clinical trials can help improve cancer treatments for patients with metastatic renal cell carcinoma (RCC), a largely incurable and lethal disease. He also shares recent statistics on the low clinical enrollment numbers as well as how many could potentially be enrolling for newer treatments.
With combinations on the horizon, the latest estimate of 5% of patients enrolled in clinical trials is a problem in the field, says Choueiri. While not all patients will be eligible for clinical trials, it still is too low of a number for cancer research to continue moving forward.
Choueiri says that even doubling that number to 10% of patients could make a big difference and at least give researchers answers they need to continue moving forward.
For more resources and information regarding anticancer targeted therapies in renal cell carcinoma: [ Ссылка ]
